Electromed's 14th Straight Quarter: ePrescribe and Bronchiectasis Awareness Keep the Engine Humming
Q3 FY2026 delivers 18.4% revenue growth and 76% operating income growth; the company pushes deeper into a large underdiagnosed market.
ELMD · Earnings Call · 2026-05-12
Another Quarter, Another Record
Electromed reported another strong quarter on May 12, 2026, its 14th consecutive quarter of year-over-year revenue and profit growth. Revenue reached $18.6M, up 18.4% from the prior year, with operating income jumping 76% to $3.8M and diluted EPS up 67% to $0.35. This performance was broad based: the flagship Home Care segment grew 19%, hospital revenue surged 43% from a slow Q2, and distributor revenue grew 3%. The company also maintained a clean balance sheet with $17M in cash and no debt.A key driver was a continued expansion of the direct sales force. The company finished the quarter with 58 reps, up from 57 average in the quarter, and has since added 4 more to reach 62 filled territories. CEO Jim Cunniff explained on the call: “We ended the quarter with 58 reps. As I've been indicating all year, we intended to have 61 territories by the end of our fiscal year. We're now at 62 territories filled.” — James Cunniff, CEO · 2026-05-12 That rep productivity continues to outpace the target range. The annualized home care revenue per fully-weighted rep hit $1.168M, exceeding the $1.0–$1.1M guidance for the second straight quarter. Operating margin expanded to 20.3% (from 13.6% a year ago) — a trend the CFO flagged as "not a new normal," but the underlying fundamentals reflect strong operating leverage. Operating MarginQ3 marks our 14th consecutive quarter of year-over-year revenue and profit growth. We delivered revenue of $18.6 million, representing 18.4% growth compared to the prior year.
The Untapped Bronchiectasis Opportunity
The company's strategic focus remains on the underdiagnosed bronchiectasis market, where the message is beginning to resonate. Management highlighted that roughly 923,000 patients are diagnosed in the U.S., but only 16% are using high-frequency chest wall oscillation therapy. Nearly 800,000 diagnosed patients are not receiving this life-changing therapy, and an estimated 4 million more may be undiagnosed. The ePrescribe solution (dubbed Smart Order) is gaining traction — over 40% of orders came through that channel in Q3, reducing average days-to-ship by 5 days versus fax orders. This gain is particularly timely as CMS phases out fax-based order submissions by May 2028.Management also stressed the complementary role of new drug entrants. The bronchiectasis patients who benefit from airway clearance are not served by drugs that only address inflammation. As the team reiterated, the drug is an adjunct, not a replacement. This narrative aligns with prior quarters: “But the drug does not clear the airways.” — Jim Cunniff, President and Chief Executive Officer · 2025-08-26 The company's Airway Clearance position remains defensible, underscored by a robust gross margin of 78.8% and a clean balance sheet. The manufacturing optimization plan is complete, providing capacity for future growth while maintaining on-time delivery in a volatile macro environment.In the third quarter, over 40% of orders came through our Smart Order solution, resulting in a 5-day reduction in average days to ship versus fax orders.